...KRAS (exon 1). Gene amplification for EGFR was analyzed by quantitative real-time PCR. HPV was detected by PCR and in-si...
...KRAS mutations (over 90%). This pilot study evaluated plasma KRAS mutations for disease monitoring in LAPC pts treated o...
...KRAS mutation (pancreas, PD), 1 of 8 had EGFR amplification by FISH (heavily pre-treated breast, SD). Additional planned...
...KRAS mutations (codon 12, 13) were detected in 9/31 (29%) pts. Disease control at 8 weeks was seen in 41% of pts with KR...
...KRAS in relation to outcome of treatment. No significant financial relationships to disclose.
...Kras mutations using different biological techniques, and mutations of the p53 gene (exons 5 to 9) by sequence analysis....
...KRAS mutations. The presence of a KRAS mutation contraindicates EGFR TKI therapy indicating other agents, or investigati...
...KRAS gene mutation ratio was 12.7% (7/55). Inverse relationship between KRAS and EGFR mutations in the non-small-cell lu...
...KRAS mutation. No other KRAS mutant case was scored as EGFR-amplified by either method. EGFR was positive by IHC in 28 c...
...KRAS mutations cannot account for all resistant cases. Preclinical data suggested that MET could interfere with anti-EGF...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
